The rate of HER2-positivity in the primary tumor was significantly correlated with the HR of PR-gain (−/+) on the OS analysis (p = 0.034) (Supplementary Table S7 and Supplementary Fig. S6). The gene discussed is ERBB2; the disease is neoplasm.